AMRN just tanked 30%.... be cautious here folks.. this company has
to yet go thru a lot of vetting and approvals... and the 200dma is at 13..
Can you shorts do some dd first before spread FUD?
Sentiment: Strong Buy
A very different situation. The FDA stated that ACAD need not run a second Phase III study because pimavanserin's data from the first Phase III was so safe and effective.